OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	753
JAMA Oncology	447
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	369
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	312
Error in Text	296
Errors in Key Points and Abstract	291
Stargazers	275
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	270
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	259
Overall Survival in the CAIRO5 Clinical Trial	238
Piercing the Fog	227
The Multidisciplinary Cancer Conference	205
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	199
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	199
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	185
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	182
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	176
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	172
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	156
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	153
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	151
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	150
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	148
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	143
Her Defiance	139

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	139
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	139
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	137
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	131
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	130
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	129
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	128
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	125
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	122
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	122
The SOUND Randomized Clinical Trial Results	113
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	113
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	107
Results of the TARGET-TP Randomized Clinical Trial	107
An Atypical Rash on the Chest	100
Immunotherapy Before Chemoradiotherapy—More Is Better?	99
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	98
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	96
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	96
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	95
Rethinking End Points in Modern Oncology Trials—Beyond the P Value	94
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	92
Trauma	91
Shifting Toward Precision Oncology in SCLC Treatment	91
JAMA Oncology	91
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	90
Coding Errors in Study of Eligibility for Lung Cancer Screening	89
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	89
Error in Text	86
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer	86
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	84
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	84
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	84
JAMA Oncology	81
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	81
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	80
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	80
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	80
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	80
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	80
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	79
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	78
Challenges in Interpreting MELATORCH Trial Outcomes—Reply	78
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	77
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	77
Variability in COVID-19 Vaccine Response Among People With Cancer	75
Clinical Trial Diversity—Will We Know It When We See It?	75
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	75
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	74
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	74

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	73
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	72
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	71
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	70
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	70
Change of Article Status to Open Access	70
JAMA Oncology	69
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	69
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	68
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	68
JAMA Oncology Peer Reviewers in 2021	67
Exposure Histories and Cancer Risk—What Can We Learn?	67
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	66
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	65
The ORATOR Trials Have Spoken—Where Do We Go From Here?	65
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	65
JAMA Oncology	65
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	64
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma	64
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	63
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	63
Characterizing Lung Cancer in Li-Fraumeni Syndrome	62
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	61
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality	60
Enlightening a Path Forward for Patients With Advanced Acral Melanoma	60
Lullaby for a Dying Self	60
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	59
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	59
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	59
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	59
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	59
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer	59
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	58
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	58
Young-Onset Colorectal Cancer Mortality by Education	58
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	58
Physical Activity, Lifestyle, and Cancer Risk	58
Global Stage Distribution of Breast Cancer at Diagnosis	57
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	57
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors	56
Endocrine Society Hypercalcemia of Malignancy Guidelines	55
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	55
Sunsets	55
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	55
JAMA Oncology	55
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	54
JAMA Oncology	53
Valid Analysis of Brain-Specific Progression-Free Survival	53
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	53
Errors in Figures 2 and 3	52
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	52
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ	52
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	52
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	51
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	51
Relentless	51
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	51
Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis	50
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	50
Error in Denominator in Results Text	50
Artificial Intelligence—From Starting Pilots to Scalable Privilege	50
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	49
The Vocabulary of Survival	49
Management of Down Syndrome–Associated Leukemias	49
Reshuffle	48
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	48
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	48
Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects	48
Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems	48
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	48
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	47
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	47
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	47
The Time for Cancer Vaccines Is Now	46
Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?—Reply	46
Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments	46
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	45
Public Awareness of the Association Between Alcohol and Cancer in the US	45
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	45
JAMA Oncology	45

Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	45
Cancer Research and Public Health Literacy—Making Sense	45
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	45
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	44
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	44
Scattered Painful Papulonodules in an Older Woman	44
The SOUND Randomized Clinical Trial Results—Reply	43
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	43
Change of Article Status to Open Access	43
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	42
Error in Figure 1	42
Dog Aloisanov Helped Diagnose My Cancer	42
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	42
Errors in Figure 3	42
Somebody Else’s Palms	42
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	42
Two Hands, One Journey	42
Financial Toxicity Among Asian American Cancer Survivors	41
Unintended Consequences of Patient Portal Access	41
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	41
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	40
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift	40
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	40
Error in Figure 1	40
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	39
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	39
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	39
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	39
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	39
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	38
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	38
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	38
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients	38
Risk Factors for Valvulopathy Among Childhood Cancer Survivors	38
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	37
Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males	37
Error in Figure	37
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	36
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	36
PARP Inhibitors for Breast Cancer Treatment	36
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	36
Error in Author Surname	35
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	35
Change to Open Access Status	35
A Case of Multiple Hemorrhagic Friable Nodules	35
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	35
An Intramedullary Enigma	35
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	34
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma	34
Change to Open Access	34
Childhood Cancer Survivor Risk Estimates and Age, Overdispersion, and Social Context—Reply	34
Overall Survival in the CAIRO5 Clinical Trial	34
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	34
Government Funding for the Development of Enzalutamide	34
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	34
Error in the Additional Contributions Section	34
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	33
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	33
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	33
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	33
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens	33
Blood Clots, or Thrombosis, in Patients With Cancer	33
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	33
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	33
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	33
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	32
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	32
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	32
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	32
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	31
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	31
Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells	31
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	30
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	30
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	30
Nontumor Cells in Tumor Samples Bias Expression-Based Models	30
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	30
Results of the TARGET-TP Randomized Clinical Trial—Reply	29
Keeping the Heartbeat Off-Target in Cancer Therapy	29
JAMA Oncology—The Year in Review, 2023	29
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship	29
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	28
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply	28
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply	28
Are Early-Onset Cancers an Example of Accelerated Biological Aging?	28
FDG PET Scans in Cancer Care	28
Errors in Table	28
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases	28
A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia	28
The Next Wave After Immunotherapy in Cancer Drug Development—Back to the Future	28
Omission of Critical Information From Clinical Trial Reports—What to Do About Uninterpretable Results	28
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer	28
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance	28
Prone Whole-Breast Radiotherapy—Better Than Supine?	28
Postoperative Management of Prostate Cancer—Optimizing Prostate Cancer Care	28